electroCore to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
ROCKAWAY, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, taking place on Wednesday, November 11, 2026, at The Westin New York Grand Central in New York City.
Joshua Lev, Co-Chief Executive Officer, President and Chief Financial Officer, will present at the conference and host one-on-one meetings with investors throughout the day.
Investors interested in scheduling a one-on-one meeting should contact their Canaccord Genuity sales representative.
About electroCore, Inc.
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

5 Stocks to Buy After Earnings

The 10 Best Dividend Stocks

2 5-Star Stocks to Buy at Big Discounts

7 Undervalued Stocks That Crushed Earnings


